Loading...
•
Mar 31, 2023
Semler Scientific Q1 2023 Earnings Report
Semler Scientific's Q1 2023 financial performance was marked by record quarterly revenues and pre-tax net income, driven predominately by sales of QuantaFlo for peripheral artery disease testing.
Key Takeaways
Semler Scientific reported a 30% increase in revenue, reaching $18.2 million, and a 48% increase in net income, amounting to $5.0 million for Q1 2023. The company's cash, cash equivalents, and short-term investments totaled $43.0 million.
Revenue increased by 30% to $18.2 million compared to Q1 2022.
Net income increased by 48% to $5.0 million compared to Q1 2022.
Cash, cash equivalents, and short-term investments totaled $43.0 million.
The company is focused on developing its business in heart dysfunction and diabetes.
Forward Guidance
Semler Scientific is focused on developing its business in two new disease areas, heart dysfunction and diabetes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...